Prospects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity
M. Yu. Grafskaya,
E. V. Verenikina,
A. Yu. Maksimov,
A. A. Demidova,
E. V. Bova,
M. I. Nazheva,
I. V. Dubatova https://doi.org/10.25789/YMJ.2025.91.05
Abstract
In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.
About the Authors
M. Yu. Grafskaya
ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России
Russian Federation
Russian Federation
E. V. Verenikina
ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России
Russian Federation
Russian Federation
A. Yu. Maksimov
ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России
Russian Federation
Russian Federation
A. A. Demidova
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
E. V. Bova
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
M. I. Nazheva
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
I. V. Dubatova
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
References
1. Рossibilities of screening for cancer of the uterine body by the content of molecular markers in urine and vaginal-cervical secretion. / Kit O.I. [et al] // Russian Clinical Laboratory Diagnostics. 2023. No 68 (3). 141-145. doi: 10.51620/0869-2084-2023-68-3-141-145
2. Savinova A.R., Gataullin I.G. Early diagnostics and screening for ovarian cancer. // Kazan medical journal. 2022. № 3 (103). С. 476-483.
3. Al-Moghrabi N., et al. Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and HighGrade Serous Ovarian Cancer in Saudi Women. Int J Mol Sci. 2024 Mar 7. No 25(6). 3108. doi: 10.3390/ijms25063108.
4. Talhouk A., et al. Development and validation of the gene expression predictor of highgrade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin. Cancer Res. 2020. 26. 5411–5423. doi: 10.1158/1078-0432.CCR-20-0103.
5. Heitz F., et al. Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer. Clin. Cancer Res. 2020. No 26. 213–219. doi: 10.1158/1078-0432.CCR-19-1741. doi: 10.1016/j.bpobgyn.2020.02.010
6. Kinde I., et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 2013. No 5. 167ra4.
7. Friedenreich C.M., Ryder-Burbidge C., McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol. Oncol. 2021. No 15. 790–800 (2021). doi: 10.1002/1878-0261.12772.
8. Gaona-Luviano P., Medina-Gaona L.A., Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020. No 9(4). 47. doi: 10.21037/cco-20-34.
9. Ramachandran D., et al. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease. NPJ Genom. Med. 2024. No 9. 19 (2024). doi: 10.1038/s41525-024-00395-y
10. Cafforio P., et al. Liquid biopsy in cervical cancer: hopes and pitfalls. Cancers. 2021. No 13. 3968. DOI: 10.3390/cancers13163968.
11. Nash Z., Menon U. Ovarian cancer screening: current status and future directions. Best Pract. Res. Clin. Obstet. Gynaecol. 2020. No 65. 32–45.
12. Hanley G.E., et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open. 2022 Feb1. No 5(2). e2147343. doi: 10.1001/jamanetworkopen.2021.47343.
13. Potenza E., et al. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer. Int J Biol Markers. 2020. No 35(4). 20–27. doi: 10.1177/1724600820955195.
14. Gersekowski K., et al. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis. Cancer Epidemiol Biomarkers Prev. 2024 Apr 3. No 33(4). 586-592. doi: 10.1158/1055-9965.
15. Funston G., et al. The diagnostic performance of CA-125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020. 17(10). e1003295. doi: 10.1371/journal.pmed.1003295.
16. Webb P.M., Jordan S.J. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024 May; No 21(5). 389-400. doi: 10.1038/s41571-024-00881-3.
Review
For citations:
Grafskaya M.Yu., Verenikina E.V., Maksimov A.Yu., Demidova A.A., Bova E.V., Nazheva M.I., Dubatova I.V. Prospects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity. Yakut Medical Journal. 2025;(3):24-28. https://doi.org/10.25789/YMJ.2025.91.05
Views:
77
Email this article 